Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.

@article{Barreiro2000RisksAB,
  title={Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.},
  author={Pablo Barreiro and Vicente Soriano and Francisco Blanco and C{\'e}sar Casimiro and J J De La Cruz and J. Gonz{\'a}lez-lahoz},
  journal={AIDS},
  year={2000},
  volume={14 7},
  pages={807-12}
}
OBJECTIVE To analyse the safety and efficacy of replacing the protease inhibitor (PI) by nevirapine (NVP) in subjects experiencing a long-term control of virus replication under a triple PI-containing antiretroviral combination. DESIGN Prospective evaluation of 138 HIV-positive subjects with plasma viral load below 50 HIV-RNA copies/ml for the last 6 months under a triple PI-containing regimen, who were randomly assigned to either replace the PI by NVP (n = 104) or continue on the same… CONTINUE READING